It is possible this upregulation of OX40L, which is known to be expressed by myeloid cells among others, in non-survivors seen in our data is reflective of early signs of additional immunologic challenge within the tumor microenvironment in patients with poor outcomes. Here, TNFSF4 is linked to neoplasm.